Log in to search using one of your social media accounts:

 

Russian scientists have studied the genes that allow cancer cells to resist drugs
(RUDN University) Researchers from the People's Friendship University of Russia (RUDN University) have studied the mechanism of drug resistance for ovarian and breast cancer cells. They discovered that these cancer cells have redox-dependent mechanism which is tasked with sustaining their drug resistance. The results have been published in two articles in the journal of Free Radical Biology and Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 22, 2017 Category: Cancer & Oncology Source Type: news

Ovarian Cancer Quiz: Test Your Medical IQ
Title: Ovarian Cancer Quiz: Test Your Medical IQCategory: MedicineNet QuizCreated: 10/18/2012 2:21:00 PMLast Editorial Review: 9/20/2017 1:00:58 PM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 20, 2017 Category: Cancer & Oncology Source Type: news

Tesaro's ovarian cancer drug gets EU agency backing
(Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer. (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bloating or bleeding: Symptoms of the FIVE gynaecological cancers YOU should know
WOMB, ovarian, cervical, vaginal and vulval cancers are the types of gynaecological cancers, but few women know the symptoms of the diseases. (Source: Daily Express - Health)
Source: Daily Express - Health - September 15, 2017 Category: Consumer Health News Source Type: news

Living With Cancer: The Crisis in Gynecological Cancer Research
We ’ re in an unusually productive phase for gynecological cancer research, but there has been a steep decline in clinical trials in the field. (Source: NYT Health)
Source: NYT Health - September 14, 2017 Category: Consumer Health News Authors: SUSAN GUBAR Tags: Clinical Trials Ovarian Cancer Drugs (Pharmaceuticals) Research Ovaries Source Type: news

Angelina Jolie Discusses Family Life After Divorce: ‘We All Have Our Difficult Times’
This article originally appeared on People.com (Source: TIME.com: Top Science and Health Stories)
Source: TIME.com: Top Science and Health Stories - September 13, 2017 Category: Consumer Health News Authors: Meoldy Chiu / People Tags: Uncategorized Angelina Jolie Brad Pitt celebrities Family society Source Type: news

Another Win for PARP Inhibition in Ovarian Cancer (CME/CE)
(MedPage Today) -- Rucaparib maintenance extends PFS in all subgroups (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 11, 2017 Category: Consumer Health News Source Type: news

A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
Rubraca Keeps Many Ovarian Cancers In Check. Could It Work As Maintenance Treatment In Pancreatic Cancer? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 11, 2017 Category: Pharmaceuticals Authors: Elaine Schattner, Contributor Tags: NASDAQ:CLVS Source Type: news

Too few women with breast cancer get genetic testing
(Reuters Health) - Some women with breast or ovarian cancer might benefit from genetic testing to guide their treatment and follow-up care, but less than one in five of those women actually get tested, a recent U.S. study suggests. (Source: Reuters: Health)
Source: Reuters: Health - September 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer
(European Society for Medical Oncology) Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news

GPs should suspect endometriosis in women with chronic pelvic pain
Delayed diagnosis is a significant problem that can worsen prognosis, warns NICE Related items fromOnMedica Ovarian cancer risk higher with endometriosis Endometriosis increases risk of miscarriage and ectopic pregnancy Endometriosis treatment 'unacceptable' (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 8, 2017 Category: UK Health Source Type: news

Vaccines are made with the same chemical found to increase breast cancer risk among women who have mutations of the BRCA genes
(Natural News) Where breast or ovarian cancer seems to “run” in a family, both male and female family members are encouraged to undergo testing to see whether they may have mutations in their BRCA1 or BRCA2 genes. These genes are responsible for suppressing tumor proteins, and when they have mutated (or altered), certain types of... (Source: NaturalNews.com)
Source: NaturalNews.com - September 5, 2017 Category: Consumer Health News Source Type: news

Your NEJM Group Today: Eosinophilic Bronchitis Images / Hereditary Breast & Ovarian Cancer Guidelines / Washington Maternal-Fetal Medicine Opportunity (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Clinical Practice Center: Image in Clinical Medicine: A 43-year-old … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 5, 2017 Category: Primary Care Source Type: news

50% Of Men Don't Know Where The Vagina Is, According To UK Study
September is Gynecological Cancer Awareness month, which aims to bring more attention and understanding of five cancers: ovarian, uterine, cervical, vaginal and vulvar. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 3, 2017 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

ICON8 trial reaffirms standard dosing in ovarian cancer chemo
(European Society for Medical Oncology) European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 3, 2017 Category: International Medicine & Public Health Source Type: news

ICER report on PARP inhibitors for ovarian cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA clears first gene-altering therapy — ‘ a living drug ’ — for childhood leukemia
The Food and Drug Administration on Wednesday approved a groundbreaking cancer treatment for childhood leukemia that uses patients' genetically altered immune cells to fight the disease. It is the first gene therapy to be cleared in the United States — a “historic” action, the agency said -- and one with major ramifications for patients with […]Related:FDA cracks down on stem-cell clinics, including one using smallpox vaccine in cancer patientsDoes talcum powder cause ovarian cancer?NIH unit deletes references to climate ‘change’ (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 30, 2017 Category: Consumer Health News Source Type: news

FDA clears first gene-altering therapy — ‘ a living drug ’ — for childhood leukemia
The Food and Drug Administration on Wednesday approved a groundbreaking cancer treatment for childhood leukemia that uses patients' genetically altered immune cells to fight the disease. It is the first gene therapy to be cleared in the United States — a “historic” action, the agency said — and one with major ramifications for patients with […]Related:FDA cracks down on stem-cell clinics, including one using smallpox vaccine in cancer patientsDoes talcum powder cause ovarian cancer?NIH unit deletes references to climate ‘change’ (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 30, 2017 Category: Consumer Health News Source Type: news

FDA approves first-of-its-kind ‘ living drug ’ for childhood leukemia
The Food and Drug Administration on Wednesday approved a groundbreaking cancer treatment for childhood leukemia that uses patients' own genetically altered immune cells to fight the disease. It is the first gene therapy to be allowed in the United States — a “historic” approval, the agency said. The decision clears the Novartis drug, called Kymriah, […]Related:FDA cracks down on stem-cell clinics, including one using smallpox vaccine in cancer patientsDoes talcum powder cause ovarian cancer?NIH unit deletes references to climate ‘change’ (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 30, 2017 Category: Consumer Health News Source Type: news

The hurricane came, and these newborns refused to wait out the storm
HOUSTON — Large swaths of South Texas ground to a halt as Harvey dumped dozens of inches of rain on everything in its path. Some schools are closed until next month. Thousands of flights were canceled. Travel was stalled for anyone without a functioning boat. But some things could not wait. Particularly, the arrival of […]Related:FDA cracks down on stem-cell clinics, including one using smallpox vaccine in cancer patientsDoes talcum powder cause ovarian cancer?Fewer antibiotic prescriptions are being filled, a new analysis finds (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 28, 2017 Category: Consumer Health News Source Type: news

FDA cracks down on stem-cell clinics, including one using smallpox vaccine in cancer patients
The Food and Drug Administration on Monday announced a crackdown on stem-cell clinics offering unproven and potentially dangerous treatments, including an operation in California that the agency said was using the smallpox vaccine on seriously ill cancer patients. U.S. marshals on Friday raided San Diego-based StemImmune and seized the vaccine, which the FDA said had […]Related:Does talcum powder cause ovarian cancer?NIH unit deletes references to climate ‘change’Tibetan Buddhism-based ‘compassion’ training for doctors targets burnout (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 28, 2017 Category: Consumer Health News Source Type: news

Cancer Tests Cheaper, Quicker With Tech
Stage I Diagnostics Inc. of Little Rock has announced a partnership with Leinco Technologies of St. Louis that will generate faster and more affordable results for blood tests that can detect ovarian and prostate cancer in their earliest forms. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - August 28, 2017 Category: American Health Source Type: news

A woman in labor showed up at a Texas hospital as the hurricane neared. She named her baby Harvey.
With more than a foot of rain falling outside and hurricane-force winds blowing on the hospital windows, Irma Rodriguez had all the problems that other residents of Corpus Christi, Tex., had on Friday night, plus two more: She hadn’t chosen a name for her baby. And it was growing clear he was not going to […]Related:Does talcum powder cause ovarian cancer?Fewer antibiotic prescriptions are being filled, a new analysis findsNIH unit deletes references to climate ‘change’ (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 27, 2017 Category: Consumer Health News Source Type: news

Does talcum powder cause ovarian cancer?
A Los Angeles jury thinks so. This week it ordered Johnson & Johnson to pay $417 million to 63-year-old Eva Echeverria. She blamed her terminal illness on Johnson's Baby Powder, which she used for decades starting at age 11. The company should have warned consumers about the risk, she […]Related:NIH unit deletes references to climate ‘change’Tibetan Buddhism-based ‘compassion’ training for doctors targets burnoutBig city health officials decry Trump administration’s cuts to teen pregnancy prevention programs (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 25, 2017 Category: Consumer Health News Source Type: news

Expert Q & A: Can Baby Powder Lead to Ovarian Cancer? Expert Q & A: Can Baby Powder Lead to Ovarian Cancer?
Epidemiologist Shelley Tworoger, PhD, sorts out what's known about talcum powder and ovarian cancer.Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 25, 2017 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Expert Interview Source Type: news

This tissue paper is made from actual organ tissues
[Image from Northwestern University]Northwestern University researchers have created biomaterials made from animal organs and tissues that could potentially support natural hormone production in young cancer patients and aid wound healing. The materials, aptly named tissue papers, are made from structural proteins that are excreted by cells and give organs their forms and structures. The tissue papers are thin and flexible enough that they can be formed into origami birds.` Researchers used ovarian, uterine, kidney, liver, muscle and heart proteins to create different types of tissue papers. The tissues were collected...
Source: Mass Device - August 24, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Regenerative Medicine Research & Development Wound Care MedTech Northwestern University organ tissue Source Type: news

Huge Underuse of Genetic Testing Among Cancer Survivors Huge Underuse of Genetic Testing Among Cancer Survivors
Clinicians need to get directly involved with genetic testing, says an expert, as new data reveal huge underuse of genetic testing for BRCA1/2 in breast/ovarian cancer survivors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 24, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

L.A. jury awards $417M in baby powder cancer lawsuit against Johnson & Johnson
A Los Angeles jury that agreed there was a connection between a woman ’s use of Johnson& Johnson talcum powder products and her terminal ovarian cancer have awarded the woman $417 million in compensatory and punitive damages. Eva Echeverria, 63, was unable to attend the trial because of her illness, but said in a recorded deposition that she used Johnson’s Baby Powder from age 11 until 2016. She was diagnosed with ovarian cancer in 2007 and is now near death, the Los Angeles Times reported. There… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 22, 2017 Category: American Health Authors: Anne Stych Source Type: news

L.A. jury awards $417M in baby powder cancer lawsuit against Johnson & Johnson
A Los Angeles jury that agreed there was a connection between a woman ’s use of Johnson& Johnson talcum powder products and her terminal ovarian cancer have awarded the woman $417 million in compensatory and punitive damages. Eva Echeverria, 63, was unable to attend the trial because of her illness, but said in a recorded deposition that she used Johnson’s Baby Powder from age 11 until 2016. She was diagnosed with ovarian cancer in 2007 and is now near death, the Los Angeles Times reported. There… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 22, 2017 Category: Biotechnology Authors: Anne Stych Source Type: news

Jury awards $417M in baby powder cancer lawsuit against Johnson & Johnson
A Los Angeles jury that agreed there was a connection between a woman ’s use of Johnson& Johnson (NYSE: JNJ) talcum powder products and her terminal ovarian cancer have awarded the woman $417 million in compensatory and punitive damages. Eva Echeverria, 63, was unable to attend the trial because of her illness, but said in a recorded deposition that she used Johnson’s Baby Powder from age 11 until 2016. She was diagnosed with ovarian cancer in 2007 and is now near death, the Los Angeles Times… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 22, 2017 Category: Biotechnology Authors: Anne Stych Source Type: news

L.A. jury awards $417M in baby powder cancer lawsuit against Johnson & Johnson
A Los Angeles jury that agreed there was a connection between a woman ’s use of Johnson& Johnson talcum powder products and her terminal ovarian cancer have awarded the woman $417 million in compensatory and punitive damages. Eva Echeverria, 63, was unable to attend the trial because of her illness, but said in a recorded deposition that she used Johnson’s Baby Powder from age 11 until 2016. She was diagnosed with ovarian cancer in 2007 and is now near death, the Los Angeles Times reported. There… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 22, 2017 Category: Biotechnology Authors: Anne Stych Source Type: news

Johnson & Johnson Ordered To Pay $417 Million In Lawsuit Linking Baby Powder To Cancer
LOS ANGELES (AP) — A Los Angeles jury on Monday ordered Johnson & Johnson to pay a record $417 million to a hospitalized woman who claimed in a lawsuit that the talc in the company’s iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene. The verdict in the lawsuit brought by the California woman, Eva Echeverria, marks the largest sum awarded in a series of talcum powder lawsuit verdicts against Johnson & Johnson in courts around the U.S. Echeverria alleged Johnson & Johnson failed to adequately warn consumers about talcum powder’s potential cancer risks. She used...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 22, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News baby powder Johnson & Johnson Source Type: news

J & J Ordered to Pay $417 Million in Trial Over Talc Cancer Risks J & J Ordered to Pay $417 Million in Trial Over Talc Cancer Risks
Johnson& Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Jury awards $417M in baby powder cancer trial
Powder verdict. A Los Angeles jury that agreed there was a connection between a woman ’s use of Johnson& Johnson talcum powder products and her terminal ovarian cancer have awarded the woman $417 million in compensatory and punitive damages. Eva Echeverria, 63, was unable to attend the trial because of her illness, but said in a recorded deposition that she used Johnson’s Baby Powder from age 11 until 2016. She was diagnosed with ovarian cancer in 2007 and is now near death, the Los Angeles… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 22, 2017 Category: Pharmaceuticals Authors: Anne Stych Source Type: news

Johnson & Johnson ordered to pay $417M in trial over talc cancer risks
A California jury on Monday ordered Johnson & Johnson to pay $417 million US to a woman who claimed she developed ovarian cancer after using the company's talc-based products. (Source: CBC | Health)
Source: CBC | Health - August 22, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

$417 Million Awarded in Suit Tying Johnson ’ s Baby Powder to Cancer
A Los Angeles jury voted the damages for a medical receptionist who developed ovarian cancer after using Johnson& Johnson ’ s talc for decades. (Source: NYT Health)
Source: NYT Health - August 22, 2017 Category: Consumer Health News Authors: RONI CARYN RABIN Tags: Ovarian Cancer Decisions and Verdicts Johnson & Hazardous and Toxic Substances Suits and Litigation (Civil) Source Type: news

Retaining one normal BRCA gene in breast, ovarian cancers influences patient survival
(University of Pennsylvania School of Medicine) Researchers found a relationship between the genetics of tumors with germline BRCA1/2 mutations and whether the tumor retains the normal copy of the BRCA1/2 gene, and risk for primary resistance to a common chemotherapy that works by destroying cancer cells' DNA. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 22, 2017 Category: Cancer & Oncology Source Type: news

Johnson & Johnson pay after talcum powder linked to cancer
A Los Angeles jury on Monday ordered Johnson& Johnson to pay $417million to Eva Echeverria, 63, who was diagnosed with ovarian cancer in 2007, after 40 years of using talcum. (Source: the Mail online | Health)
Source: the Mail online | Health - August 21, 2017 Category: Consumer Health News Source Type: news

Johnson & Johnson ordered to pay $417 million in talcum powder case
On Monday, a jury awarded a California woman $417 million because she developed ovarian cancer and had used Johnson& Johnson Baby Powder for decades. The award includes $70 million in compensatory damages and $347 million in punitive damages. (Source: CNN.com - Health)
Source: CNN.com - Health - August 21, 2017 Category: Consumer Health News Source Type: news

Johnson & Johnson faces $417m payout in latest talc case
The payout - to a woman who developed ovarian cancer - is the largest award so far against the firm. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 21, 2017 Category: Consumer Health News Source Type: news

Johnson & Johnson ordered to pay $417M in baby powder lawsuit
Lawsuit claims talc in the company's iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 21, 2017 Category: Consumer Health News Source Type: news

Record $417M award in lawsuit linking baby powder to cancer
A Los Angeles jury has ordered Johnson & Johnson to pay $417 million in a case to a woman who claimed in lawsuit that the talc in its iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene (Source: ABC News: Health)
Source: ABC News: Health - August 21, 2017 Category: Consumer Health News Tags: Health Source Type: news

The Latest: Plaintiff wanted to help others in talc case
The attorney for a hospitalized woman who won a $417 million judgment in a lawsuit claiming the talc in Johnson & Johnson's iconic baby powder causes ovarian cancer says his client is not looking for sympathy (Source: ABC News: Health)
Source: ABC News: Health - August 21, 2017 Category: Consumer Health News Tags: Health Source Type: news

Jury awards $417M in lawsuit linking talcum powder to cancer
A Los Angeles jury has ordered Johnson & Johnson to pay $417 million in a case to a woman who claimed in lawsuit that the talc in its iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene (Source: ABC News: Health)
Source: ABC News: Health - August 21, 2017 Category: Consumer Health News Tags: Health Source Type: news

J & J ordered to pay $417 million in trial over talc cancer risks
(Reuters) - Johnson& Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene. (Source: Reuters: Health)
Source: Reuters: Health - August 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Olaparib Now Approved as Maintenance Therapy, and in Tablet Form
The FDA approved olaparib as maintenance therapy for adult patients with recurrent ovarian cancer. The agent is also now approved in tablet form. (Source: CancerNetwork)
Source: CancerNetwork - August 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Ovarian Cancer Source Type: news

Few women with history of breast cancer and ovarian cancer take a recommended genetic test
UCLA HealthDr. Christopher ChildersOf the nearly 4 million women in the United States who have had either breast cancer or ovarian cancer, at least 1.5 million have a high risk of carrying certain types of genetic mutations that could increase their risk for additional cancers in the future.And although the mutations, including those that affect the BRCA1 and BRCA2 genes, can be identified through a simple blood or saliva test, more than 80 percent of those women have not taken the test or even discussed it with a health care provider, according to a new study from the  UCLA Fielding School of Public Health.The study ...
Source: UCLA Newsroom: Health Sciences - August 19, 2017 Category: Universities & Medical Training Source Type: news

'Junk food' may increase cancer risk in 'healthy weight' women
"Women who eat junk food such as burgers or pizza are increasing their risk of cancer even if they're not overweight, new research has warned," reports the Daily Mail. The story is based on research from the US looking at the diet of postmenopausal women in the 1990s and then tracking the development of a variety of cancers over about 15 years. "Junk food" is often defined as food that is rich in calories (energy dense food) but low in nutrients. Having a diet high in energy dense foods, such as biscuits, chocolate and pizza was found to increase the risk of cancer in these women, specifically in those ...
Source: NHS News Feed - August 18, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Few women with history of breast cancer and ovarian cancer take a recommended genetic test
(University of California - Los Angeles Health Sciences) More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 18, 2017 Category: Cancer & Oncology Source Type: news

FDA expands use of AstraZeneca/Merck ovarian cancer drug
(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck& Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. (Source: Reuters: Health)
Source: Reuters: Health - August 17, 2017 Category: Consumer Health News Tags: healthNews Source Type: news